Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
C 147.06 -1.10% -1.64
ASND closed down 1.1 percent on Monday, March 18, 2024, on 50 percent of normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
Multiple of Ten Bearish Other 0.00%
Down 3 Days in a Row Weakness 0.00%
20 DMA Resistance Bearish -1.10%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.10%
Multiple of Ten Bearish Other -1.10%
Gapped Up Strength -1.10%
Fell Below 20 DMA Bearish -1.89%
Multiple of Ten Bearish Other -1.89%
Outside Day Range Expansion -1.89%
20 DMA Support Bullish -4.49%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 13 hours ago
Up 1% about 13 hours ago
10 DMA Support about 13 hours ago
Rose Above 10 DMA about 13 hours ago
Fell Below Previous Day's Low about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ascendis Pharma A/S Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Breakthrough Therapy Hormones Pulmonary Arterial Hypertension Peptide Hormones Drug Therapies Growth Hormone Treatment Of Diabetes Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil

Is ASND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 161.0
52 Week Low 64.33
Average Volume 383,896
200-Day Moving Average 108.03
50-Day Moving Average 143.13
20-Day Moving Average 151.53
10-Day Moving Average 149.11
Average True Range 5.25
RSI (14) 48.98
ADX 15.82
+DI 18.34
-DI 18.31
Chandelier Exit (Long, 3 ATRs) 145.24
Chandelier Exit (Short, 3 ATRs) 157.77
Upper Bollinger Bands 160.48
Lower Bollinger Band 142.58
Percent B (%b) 0.25
BandWidth 11.82
MACD Line 1.67
MACD Signal Line 2.64
MACD Histogram -0.9687
Fundamentals Value
Market Cap 8.33 Billion
Num Shares 56.6 Million
EPS -9.21
Price-to-Earnings (P/E) Ratio -15.97
Price-to-Sales 30.12
Price-to-Book 14.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 152.99
Resistance 3 (R3) 153.56 152.14 152.00
Resistance 2 (R2) 152.14 150.63 151.86 151.67
Resistance 1 (R1) 149.60 149.70 148.89 149.04 151.34
Pivot Point 148.19 148.19 147.83 147.90 148.19
Support 1 (S1) 145.65 146.67 144.94 145.08 142.78
Support 2 (S2) 144.23 145.74 143.95 142.45
Support 3 (S3) 141.69 144.23 142.12
Support 4 (S4) 141.13